{"id":1068258,"date":"2022-06-09T01:55:10","date_gmt":"2022-06-09T05:55:10","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/terns-pharmaceuticals-to-present-clinical-data-on-multiple-nash-programs-at-the-easl-international-liver-congress-2022\/"},"modified":"2024-08-18T11:45:01","modified_gmt":"2024-08-18T15:45:01","slug":"terns-pharmaceuticals-to-present-clinical-data-on-multiple-nash-programs-at-the-easl-international-liver-congress-2022","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/terns-pharmaceuticals-to-present-clinical-data-on-multiple-nash-programs-at-the-easl-international-liver-congress-2022.php","title":{"rendered":"Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022"},"content":{"rendered":"<p><![CDATA[FOSTER CITY, Calif., June  08, 2022  (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (\u201cTerns\u201d or the \u201cCompany\u201d) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer, today announced that five abstracts detailing clinical data for multiple non-alcoholic steatohepatitis (NASH) programs within the Company's portfolio were accepted for presentation at The International Liver Congress\u2122 2022 taking place June 22-26 in London, United Kingdom. The\u00a0abstracts were published in the July supplement of the Journal of Hepatology.]]><\/p>\n<p>Read more here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/06\/08\/2459187\/0\/en\/Terns-Pharmaceuticals-to-Present-Clinical-Data-on-Multiple-NASH-Programs-at-the-EASL-International-Liver-Congress-2022.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022\">Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068258","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068258"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068258"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068258\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}